Status:
COMPLETED
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
Lead Sponsor:
ZymoGenetics
Conditions:
Melanoma
Kidney Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any e...
Detailed Description
This is a phase 1 safety study. Everyone enrolled and eligible will be given rIL-21. The study has 2 parts, Part A will determine how high a dose of rIl-21 can be safely given to patients with these t...
Eligibility Criteria
Inclusion
- 18 years and older with stage 4 metastatic malignant melanoma or stage 4 metastatic kidney cancer
- ECOG status of 0 or 1
- Patients must have adequate liver, kidney and bone marrow function
Exclusion
- Known ocular melanoma
- Suspected or confirmed brain metastases
- Patient cannot have had a bone marrow transplant
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00095108
Start Date
May 1 2004
End Date
January 1 2007
Last Update
March 9 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109
2
University of Washington/Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109